TO: MassHealth Accountable Care Partnership Plans and Managed Care Organizations

FROM: Daniel Tsai, Assistant Secretary for MassHealth

RE: MassHealth ACPP/MCO Uniform Preferred Drug List

Background

This bulletin communicates changes to the December 2019 version of the MassHealth Drug List, including the MassHealth ACPP/MCO Uniform Preferred Drug List, and corresponding actions that MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) must take pursuant to Section 2.6.B.4 of their respective ACPP and MCO contracts with MassHealth. The MassHealth Drug List (MHDL) can be found online at https://masshealthdruglist.ehs.state.ma.us/MHDL/.

Updates to Hepatitis C Virus (HCV) Preferred Drug Products

Effective January 1, 2020, MassHealth removed Vosevi (sofosbuvir/velpatasvir/voxilaprevir) from the preferred product drug list.

Within 90 days of the effective date, and no later than April 1, 2020, MassHealth ACPPs and MCOs must update their respective drug lists or formularies within the therapeutic class of Hepatitis C agents to align their preferred drug policies with the preferred drugs in the MHDL. However, MassHealth ACPPs and MCOs must allow any patients who have initiated therapy prior to the implementation date of the formulary update to complete their course of treatment without a change in product.

MassHealth Website

This bulletin is available on the MassHealth website at www.mass.gov/masshealth-provider-bulletins.

To sign up to receive email alerts when MassHealth issues new bulletins and transmittal letters, send a blank email to join-masshealth-provider-pubs@listserv.state.ma.us. No text in the body or subject line is needed.

Questions

If you have questions about the information in this bulletin, please contact the MassHealth Customer Service Center at (800) 841-2900, email your inquiry to providersupport@mahealth.net, or fax your inquiry to (617) 988-8974.